logo
Sign in

GOSS Stock Price, Chart, Stats & News

Gossamer Bio, Inc.
Save
39.64M
Market cap
Current P/E
Forward P/E

GOSS chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
99.53%
Operating margin
-352.23%
Pretax margin
-351.67%
Net margin
-351.49%
Effective tax rate
0.05%
ROA
-98.91%
ROE
264.70%
D/E
-1.65x
Interest coverage ratio
-15.54x

GOSS valuation

P/E
P/S
1.68x
P/B
-0.64x
P/CF
-0.46x
P/FCF
-0.47x
P/OCF
-0.46x
PEG
0.05x
EV multiple
0.52x

About

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.

Similar securities

Based on sector and market capitalization

Report issue